Home › Research › Long-term cohort studies
Circulating fibroblast growth factor 23 levels and incident dementia: The Framingham heart study
McGrath ER, Himali JJ, Levy D, Conner SC, Pase MP, Abraham CR, Courchesne P, Satizabal CL et al.. PloS one, 2019-03-04
Topic: Risk, prevention and care in population studies
Background Fibroblast growth factor 23 is an emerging vascular biomarker, recently associated with cerebral small vessel disease and poor cognition in patients on dialysis. It also interacts with klotho, an anti-aging and cognition enhancing protein. Objective To determine if circulating Fibroblast growth factor 23 (FGF23) is associated with new-onset cognitive outcomes in a community-based cohort of cognitively healthy adults with long-term follow-up.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
McGrath, E. R., Himali, J. J., Levy, D., Conner, S. C., Pase, M. P., Abraham, C. R., et al. (2019). Circulating fibroblast growth factor 23 levels and incident dementia: The Framingham heart study. PloS one. https://doi.org/10.1371/journal.pone.0213321
Vancouver
McGrath ER, Himali JJ, Levy D, Conner SC, Pase MP, Abraham CR, et al. Circulating fibroblast growth factor 23 levels and incident dementia: The Framingham heart study. PloS one. 2019. doi:10.1371/journal.pone.0213321. PMID: 30830941.
BibTeX
@article{mcgrath2019-30830941,
author = {McGrath, E. R. and Himali, J. J. and Levy, D. and Conner, S. C. and Pase, M. P. and Abraham, C. R. and Courchesne, P. and Satizabal, C. L. and others},
title = {{Circulating fibroblast growth factor 23 levels and incident dementia: The Framingham heart study}},
journal = {PloS one},
year = {2019},
doi = {10.1371/journal.pone.0213321},
pmid = {30830941},
url = {https://doi.org/10.1371/journal.pone.0213321}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.
Key findings
- It also interacts with klotho, an anti-aging and cognition enhancing protein.
- Objective To determine if circulating Fibroblast growth factor 23 (FGF23) is associated with new-onset cognitive outcomes in a community-based cohort of cognitively healthy adults with long-term follow-up.
- Methods We measured serum FGF23 levels in 1537 [53% women, mean age 68.7 (SD 5.7)] dementia-free Framingham Offspring participants at their 7th quadrennial examination (1998-2001), and followed these participants for the development of clinical all-cause dementia and Alzheimer's disease (AD).
- Secondary outcomes included MRI-based structural brain measures, and neurocognitive test performance at exam 7.
Why it matters
In a community-based group of older adults, this study examined whether blood levels of fibroblast growth factor 23 (FGF23) were linked to new cases of dementia or cognitive problems. It is about a possible risk marker and does not test any treatment, cure, or prevention.
Study details
- Effect size7.9%; 5.9%
- Evidence strengthModerate
How this study scored 53/100
Published in a peer-reviewed journal. Scored zero for study design, sample size, studied in people and randomised / blinded because the record does not state it.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (PloS one) |
| Journal's citation record | 4 / 4 | PLoS ONE: journal h-index 594 (OpenAlex, 2026-10-29) |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 3 / 5 | Rated “moderate” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 2 / 5 | 2019 — within 10 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 2 / 3 | Effect reported as a number, without an interval or test |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomised / blinded | 0 / 2 | No randomisation or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 4 / 7 | Cited 51 times (OpenAlex, 2026-10-10) |
| Citations per year | 2 / 5 | 5.7 citations a year over 9 year(s) since 2019 |
| Impact for its field and year | 3 / 6 | Cited 4.2× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 1 / 6 | Cited by 1 other studies in this library |
| Still being cited | 2 / 4 | Cited 20 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 4 / 4 | Last-listed author Sudha S. Seshadri: h-index 148 (OpenAlex, whole career) |
| Institution's track record | 3 / 3 | Harvard University: institution h-index 3,235 (OpenAlex) |
| Multi-centre collaboration | 2 / 3 | OpenAlex lists 7 institution(s) in 2 countries |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 30830941) |
| Free to read | 2 / 2 | Free to read |
| Total | 53 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here.
Later studies that cite this one
1 study in the alzhub library lists this one in its references.
Related studies in Long-term cohort studies
Also tagged “biobank”
1,084 studies in the library carry the topic tag “biobank”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 1,084 tagged studies.